The present invention features a composition comprising a first agent and a second agent for treating disorder associated with aberrant activity in the HPA axis like an addiction to a substance (e.g. cocaine amphetamines methamphetamine methylphenidate heroin coedine hydrocodone nicotine alcohol prescription medication (e.g. Percodan Percoset) marijuana tobacco methadone food) addiction to an activity (e.g. gambling sex eating) substance use disorders mood disorders anxiety disorders bipolar disorder sleep disorders insomnia posttraumatic stress syndrome borderline personality disorder disruptive behavior disorders ADHD major depressive disorder burnout chronic fatigue syndrome fibromyalgia irritable bowel syndrome eating disorders (e.g. Prader Willi Syndrome) obesity depression menopause prementsrual syndrome (PMS) obsessive compulsive disorder (OCD) social anxiety generalized anxiety disorder dysthymia or schizophrenia.
